Introduction {#s1}
============

3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is widely used recreationally for its euphoric effects. Additionally, recent investigations are looking into MDMA as a medication to assist psychotherapy in patients with posttraumatic stress disorder (PTSD) ([@B1]--[@B3]). MDMA acts mainly as a releaser and reuptake inhibitor of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) *via* an interaction with the respective transporter ([@B4]--[@B7]). The subjective effects of MDMA have been shown to mainly depend on transporter-mediated release of 5-HT and NE ([@B8]). In animals, however, the possibility was raised that the importance of interaction with the DA system would increase with the amount of drug taken ([@B9]). To what extent DA is mediating the acute effects of MDMA in humans is unclear. For example, the positive effects of MDMA were diminished after pharmacological inhibition of DA receptors with haloperidol ([@B10]). In addition, MDMA-induced hyperactivity was reduced in knockout mice without the DA receptor D~2~ gene (DRD2) ([@B11]). However, in contrast to the strongly diminished effect of MDMA in subjects with a blocked serotonin transporter, preventing the interaction of MDMA with the DA transporter (DAT) by pretreatment with bupropion or methylphenidate had no effect on the acute mood effects of MDMA in humans ([@B12]--[@B15]). Studies on the influence of genetic polymorphisms in the DA system could add adjuvant information to this matter and may also explore the role of the DA system in the interindividual differences in the response to MDMA. So far, only genetic variations of the enzymes that are involved in MDMA metabolism (mainly CYP2D6) displayed a robust influence on MDMA plasma levels in several clinical studies ([@B16]--[@B18]) and also showed a concomitant modulation of the pharmacodynamic effects of MDMA. However, genetic variants of pharmacological targets of MDMA may also alter its pharmacodynamic effects. A few studies explored the role of genetic polymorphisms of the 5-HT, NE, and oxytocin systems and found only minimal influences on acute effects of MDMA ([@B19]--[@B23]).

The DAT is a key target for many stimulant-type drugs, including cocaine, amphetamine, methylphenidate, and MDMA ([@B6], [@B24]). Additionally, the transporter is involved in various psychiatric disorders and treatment approaches ([@B25]--[@B27]). Subsequently, genetic polymorphisms within the single copy gene coding for the DAT (DAT1, SLC6A3) were investigated in relation to cocaine dependence and abuse, methamphetamine psychosis, attention-deficit/hyperactivity disorder (ADHD) and treatment, and bipolar disorder ([@B28]--[@B36]). Two common variable-number tandem repeat (VNTR) polymorphisms were most extensively studied. One, the rs28363170, is located in the 3′ untranslated region (3′UTR) of the DAT1 gene and exhibits 9 or 10 repeats as most common forms ([@B37]). Homozygous carriers of the 9-repeat allele were found to be at a higher risk for persistent ADHD, and the 10/10 genotype was associated with ADHD in children ([@B38]). Subjects with the 9/9 genotype were less susceptible to the subjective effects of amphetamine ([@B39]). However, carriers of at least one 9-repeat allele showed higher ratings of "high," "any drug effect," "anxious," and "stimulated" after cocaine ([@B40]). Conversely, homozygous 10-repeat carriers in combination with a 5-repeat allele of the other extensively studied VNTR in the DAT1, the rs3836790, displayed a lower response to "good drug effects," "bad drug effects," "depressed," and "anxious" ([@B40]). The rs3836790 VNTR is located in intron 8 of the human DAT1 gene. The most common forms of this VNTR are 5 or 6 repeats ([@B30]). A study in a Brazilian sample found a positive association of the 6-repeat allele and cocaine addiction ([@B28]). In contrast, another yet smaller case-control study in a Spain sample showed an overrepresentation of the 5/5 genotype in cocaine abusers ([@B33]).

MDMA also directly and indirectly interacts with DA receptors ([@B4]). Especially the inhibition of the D~2~ with haloperidol showed a significant reduction in MDMA positive effects ([@B10]). MDMA-unrelated pharmacogenetic studies showed a positive association of the minor allele of the DRD2 single-nucleotide polymorphisms (SNPs) rs1079597 and rs1800497 with heroin dependence ([@B41]), rs6277 and rs1800497 with nicotine dependence ([@B42]), and rs6277 with alcohol dependence in males ([@B43]). The VNTR polymorphism within the gene coding for the subtype 4 of the DA receptors (DRD4) is also frequently studied in relation to psychiatric disorders and personality traits ([@B44]--[@B47]). DRD4 VNTR variations range from 2 repeats to 10 repeats, with 4 and 7 repeats as the most frequent forms ([@B48]). The presence of a 7-repeat allele has been linked with personal traits like high novelty seeking, risky decision making, and broad sexual interest ([@B44], [@B47]). Moreover, children and adolescents suffering from ADHD and carrying the 7-repeat allele had to take higher doses of methylphenidate to reach sufficient efficacy ([@B49]). This finding is in line with earlier results from an *in vitro* study showing a reduced sensitivity of the 7-repeat allele toward DA compared with the 2- and 4-repeat allele ([@B50]).

The present study is the first to explore the influence of variants within genes coding for the DA system on the acute effects of MDMA in humans. We analyzed DRD2/ANKK1 rs1800497, DRD2 rs6277, and rs107959, DAT1 rs28363170, rs3836790, rs6347, rs11133767, rs11564774, rs460000, and rs463379, DRD4 VNTR and their influence on acute subjective and autonomic effects of MDMA. Given the partially inconclusive pharmacogenetic studies in addition to the unclear degree to which MDMA effects are driven by the interaction with the DA system, we hypothesized that genetic mutations of the DA system would not influence cardiostimulant effects and have only minimal influence on the mood effects of MDMA.

Methods {#s2}
=======

Study Design {#s2_1}
------------

This was a pooled analysis of nine double-blind, placebo-controlled, crossover studies that used similar methods and were conducted in healthy subjects and in the same laboratory ([@B14], [@B15], [@B51]--[@B55]). The studies included a total of 164 healthy subjects. Seven studies included 16 subjects each, for a total of 112 subjects, who received 125 mg MDMA twice, once alone and once after pretreatment with a medication ([@B14], [@B15], [@B51]--[@B54]). Two additional studies included 24 and 28 subjects who received 125 mg MDMA alone, placebo, or other treatments ([@B55]; Holze et al., unpublished). In the present analysis, only data from the MDMA-alone and placebo sessions were used. In all of the studies, the washout periods between single-dose administrations of MDMA were at least 7 days to exclude possible carryover effects. The studies were all registered at ClinicalTrials.gov (NCT00886886, NCT00990067, NCT01136278, NCT01270672, NCT01386177, NCT01465685, NCT01771874, NCT01951508, and NCT03019822). All of the studies were approved by the local ethics committee and, if necessary, Swiss Agency for Therapeutic Products (Swissmedic). The studies were conducted in accordance with the Declaration of Helsinki. MDMA administration in healthy subjects was authorized by the Swiss Federal Office for Public Health (BAG), Bern, Switzerland. Written informed consent was obtained from all of the participants. All of the subjects were paid for their participation. Detailed pharmacokinetic and safety data from these studies have been reported elsewhere ([@B17], [@B18], [@B56]). Test sessions were conducted in a quiet hospital research ward with no more than two research subjects present per session. The participants were comfortably lying in hospital beds and were mostly listening to music and not engaging in physical activities. MDMA was given without food in the fasting state in the morning at 8:00--9:00 AM. A small standardized lunch was served at 12:00--1:00 PM.

Subjects {#s2_2}
--------

A total of 164 healthy subjects of European descent, 18--45 years old (mean ± SD = 25.3 ± 4 years), were recruited from the University of Basel campus and participated in the study. One genotyping sample was missing, three participants did not give consent for genotyping, and 11 subjects participated twice (only one participation that included all outcome measures was used), resulting in a final data set of 149 subjects (76 women). The mean ± SD body weight was 69 ± 11 kg (range: 46--97 kg).

The exclusion criteria included a history of psychiatric disorders, physical illness, a lifetime history of illicit drug use more than 10 times (with the exception of past cannabis use), illicit drug use within the past 2 months, and illicit drug use during the study, as determined by urine tests that were conducted before the test sessions, as reported in detail elsewhere ([@B52]--[@B54]). Fifty-five subjects had prior illicit drug experiences (1--8 times), of which 27 subjects had previously used MDMA (1--5 times), 14 subjects had previously used amphetamine or methamphetamine (1--2 times), 11 subjects had previously used cocaine (1--4 times), eight subjects had previously used lysergic acid diethylamide (1--2 times), and 11 subjects had previously used psilocybin (1--4 times).

Study Drug {#s2_3}
----------

(±)MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was administered orally in a single dose of 125 mg prepared as gelatin capsules (25 and 100 mg). Similar amounts of MDMA are found in ecstasy pills ([@B57]) and have been used in clinical trials in patients ([@B1], [@B2]). The doses were not adjusted for body weight or sex. The dose per body weight (mean ± SD) was 1.9 ± 0.3 mg/kg (range: 1.3--2.7 mg/kg).

Physiological Effects {#s2_4}
---------------------

Blood pressure, heart rate, and body temperature were assessed repeatedly before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo administration. Systolic and diastolic blood pressures and heart rate were measured using an automatic oscillometric device (OMRON Healthcare Europe NA, Hoofddorp, Netherlands). The measurements were performed in duplicate at an interval of 1 min and after a resting time of at least 10 min. The averages were calculated for the analysis. Mean arterial pressure (MAP) was calculated as diastolic blood pressure + (systolic blood pressure -- diastolic blood pressure)/3. The rate pressure product (RPP) was calculated as systolic blood pressure × heart rate. Core (tympanic) temperature was measured using a Genius 2 ear thermometer (Tyco Healthcare Group LP, Watertown, NY, USA). In two studies (N = 46), the 2-h time point was not used.

Pharmacodynamic Measures {#s2_5}
------------------------

Visual Analog Scales (VASs) were repeatedly used to assess subjective effects over time ([@B58]). The VASs included for instance "any drug effect," "good drug effect," and "stimulated." The VASs were presented as 100 mm horizontal lines (0--100%), marked from "not at all" on the left to "extremely" on the right. Subjective effects like "concentration," "appetite," "tired," "want to be hugged," "want to hug," and "talkative" were bidirectional (±50 mm). Not all VAS components were presented in all studies. Exact numbers of subjects per genotype group are reported in [**Tables 1**](#T1){ref-type="table"}--[**3**](#T3){ref-type="table"}. The VASs were applied before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo administration. In two studies (N = 46), the 2-h time point is missing; additionally, in one study (N = 21), the 2.5-h time point is also missing.

###### 

Effects of polymorphisms in the dopamine receptor D2 gene on the maximal response to 125 mg MDMA (mean ± SD (N) and statistics) corrected with MDMA AUC~6~ (exclusive plasma concentrations).

  DRD2/ANKK1 rs1800497                         AA                    AG                   GG                    F      p value   p value^a^   η^2^
  -------------------------------------------- --------------------- -------------------- --------------------- ------ --------- ------------ -------
  N                                            2                     46                   101                                                 
  Female, N \[%\]                              1 (50)                30 \[65\]            45 \[45\]                                           
  Drug experience, N \[%\]                     2 (100)               17 \[37\]            36 \[36\]                                           
  MDMA plasma concentration Cmax, ng/ml        236 ± 76 (2)          239 ± 47 (46)        223 ± 49 (101)        1.71   NS        NS           0.023
  MDMA plasma concentration AUC~6~, ng\*h/ml   964 ± 235 (2)         994 ± 199 (46)       944 ± 205 (101)       0.97   NS        NS           0.013
  Visual Analog Scale rating ΔE~max~                                                                                                          
  Any drug effect                              84 ± 18 (2)           77 ± 23 (46)         70 ± 28 (101)         0.74   NS        NS           0.008
  Good drug effect                             94 ± 9 (2)            78 ± 26 (46)         70 ± 30 (101)         1.31   NS        NS           0.016
  Bad drug effect                              24 ± 35 (2)           21 ± 25 (46)         14 ± 24 (101)         1.14   NS        NS           0.015
  Drug liking                                  96 ± 6 (2)            78 ± 28 (46)         72 ± 29 (101)         1.03   NS        NS           0.013
  Stimulated                                   91 ± 13 (2)           68 ± 32 (46)         59 ± 35 (101)         1.44   NS        NS           0.018
  High mood                                    96 ± 6 (2)            73 ± 30 (46)         66 ± 34 (101)         0.98   NS        NS           0.012
  Concentration                                28 ± 31 (2)           6.2 ± 14 (46)        9.2 ± 16 (101)        2.09   NS        NS           0.028
  Talkative                                    48 ± 4 (2)            18 ± 20 (46)         22 ± 18 (101)         3.12   0.047\*   NS           0.040
  Appetite                                     7.5 ± 9.2 (2)         -5.3 ± 39 (23)       -8.9 ± 27 (47)        0.43   NS        NS           0.012
  Tired                                        24 ± 8 (2)            19 ± 34 (33)         20 ± 32 (74)          0.07   NS        NS           0.001
  Fear                                         7.0 ± 9.9 (2)         7.3 ± 15 (31)        5.9 ± 17 (64)         0.06   NS        NS           0.001
  Happy                                        50 (1)                26 ± 19 (32)         27 ± 19 (73)          0.63   NS        NS           0.011
  Want to be hugged                            NA (0)                13 ± 18 (23)         13 ± 19 (54)          0.12   NS        NS           0.001
  Want to hug                                  NA (0)                14 ± 17 (23)         13 ± 18 (54)          0.02   NS        NS           0.000
  Vital signs parameters ΔE~max~                                                                                                              
  Systolic blood pressure, mmHg                21 ± 31 (2)           25 ± 11 (46)         23 ± 13 (101)         0.32   NS        NS           0.004
  Diastolic blood pressure, mmHg               13 ± 11 (2)           15 ± 10 (46)         13 ± 9 (101)          0.78   NS        NS           0.010
  Mean arterial pressure, mmHg                 14 ± 22 (2)           19 ± 10 (46)         16 ± 9 (101)          0.91   NS        NS           0.011
  Heat rate beat/min                           31 ± 33 (2)           20 ± 15 (46)         16 ± 13 (101)         2.07   NS        NS           0.027
  Rate pressure product, mmHg/min              6,343 ± 6,658 (2)     4,967 ± 2,855 (46)   4,203 ± 2,776 (101)   1.26   NS        NS           0.017
  Body temperature, °C                         0.5 ± 0.1 (2)         0.2 ± 0.4 (46)       0.2 ± 0.5 (101)       0.34   NS        NS           0.005
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                  
  Activity                                     10 ± 8 (2)            2.1 ± 4.2 (46)       2.4 ± 5.3 (101)       2.40   0.09      NS           0.032
  High mood                                    7.5 ± 0.7 (2)         2.2 ± 2.8 (46)       3.0 ± 3.2 (101)       3.49   0.033\*   NS           0.046
  Fear/depression                              -1.5 ± 2.1 (2)        1.2 ± 3.3 (46)       1.2 ± 3.4 (101)       0.63   NS        NS           0.009
  DRD2 rs6277                                  AA                    AG                   GG                    F      p value   p value^a^   η^2^
  N                                            50                    73                   26                                                  
  Female, N \[%\]                              25 \[50\]             39 \[53\]            12 \[46\]                                           
  Drug experience, N \[%\]                     18 \[36\]             29 \[40\]            8 \[31\]                                            
  MDMA plasma concentration Cmax, ng/ml        225 ± 52 (50)         233 ± 47 (73)        221 ± 47 (26)         0.70   NS        NS           0.009
  MDMA plasma concentration AUC~6~, ng\*h/ml   949 ± 213 (50)        974 ± 203 (73)       939 ± 186 (26)        0.38   NS        NS           0.005
  Visual Analog Scale rating ΔE~max~                                                                                                          
  Any drug effect                              70 ± 31 (50)          73 ± 25 (73)         77 ± 21 (26)          0.95   NS        NS           0.011
  Good drug effect                             72 ± 31 (50)          74 ± 26 (73)         71 ± 31 (26)          0.04   NS        NS           0.000
  Bad drug effect                              11 ± 21 (50)          16 ± 24 (73)         25 ± 30 (26)          3.42   0.036\*   NS           0.043
  Drug liking                                  74 ± 30 (50)          74 ± 26 (73)         73 ± 34 (26)          0.01   NS        NS           0.000
  Stimulated                                   57 ± 37 (50)          63 ± 33 (73)         71 ± 32 (26)          1.63   NS        NS           0.020
  High mood                                    67 ± 33 (50)          70 ± 32 (73)         67 ± 36 (26)          0.09   NS        NS           0.001
  Concentration                                10 ± 16 (50)          6.3 ± 15 (73)        12 ± 18 (26)          1.59   NS        NS           0.021
  Talkative                                    22 ± 18 (50)          20 ± 19 (73)         22 ± 20 (26)          0.25   NS        NS           0.003
  Appetite                                     -17 ± 32 (26)         -0.8 ± 30 (35)       -4.5 ± 25 (11)        2.26   NS        NS           0.061
  Tired                                        23 ± 33 (36)          20 ± 33 (55)         14 ± 29 (18)          0.44   NS        NS           0.008
  Fear                                         4.5 ± 10 (35)         5.7 ± 14 (47)        13 ± 29 (15)          1.64   NS        NS           0.034
  Happy                                        29 ± 18 (32)          26 ± 20 (53)         27 ± 18 (21)          0.30   NS        NS           0.005
  Want to be hugged                            13 ± 18 (24)          13 ± 19 (38)         12 ± 17 (15)          0.08   NS        NS           0.002
  Want to hug                                  12 ± 17 (24)          14 ± 19 (38)         13 ± 16 (15)          0.01   NS        NS           0.000
  Vital signs parameters ΔE~max~                                                                                                              
  Systolic blood pressure, mmHg                24 ± 13 (50)          23 ± 13 (73)         24 ± 11 (26)          0.10   NS        NS           0.001
  Diastolic blood pressure, mmHg               13 ± 9 (50)           14 ± 8 (73)          14 ± 13 (26)          0.08   NS        NS           0.001
  Mean arterial pressure, mmHg                 17 ± 10 (50)          17 ± 9 (73)          18 ± 11 (26)          0.16   NS        NS           0.002
  Heat rate beat/min                           19 ± 14 (50)          16 ± 15 (73)         20 ± 14 (26)          1.57   NS        NS           0.021
  Rate pressure product, mmHg/min              4,635 ± 2,630 (50)    4,211 ± 3,111 (73)   4,867 ± 2,541 (26)    0.85   NS        NS           0.011
  Body temperature, °C                         0.3 ± 0.6 (50)        0.2 ± 0.5 (73)       0.2 ± 0.4 (26)        0.42   NS        NS           0.006
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                  
  Activity                                     2.6 ± 5.7 (50)        2.2 ± 4.9 (73)       2.7 ± 4.5 (26)        0.15   NS        NS           0.002
  High mood                                    3.1 ± 3.2 (50)        2.9 ± 3.2 (73)       2.1 ± 3.0 (26)        0.84   NS        NS           0.012
  Fear/depression                              0.7 ± 3 (50)          1.3 ± 3.1 (73)       1.5 ± 4.5 (26)        0.79   NS        NS           0.011
  DRD2 rs1079597                               CC                    CT                   TT                    F      p value   p value^a^   η^2^
  N                                            111                   37                   1                                                   
  Female, N \[%\]                              53 \[48\]             22 \[59\]            1 \[100\]                                           
  Drug experience, N \[%\]                     40 \[36\]             14 \[38\]            1 \[100\]                                           
  MDMA plasma concentration Cmax, ng/ml        226 ± 49 (111)        234 ± 49 (37)        290 (1)               1.19   NS        NS           0.016
  MDMA plasma concentration AUC~6~, ng\*h/ml   949 ± 202 (111)       985 ± 208 (37)       1130 (1)              0.78   NS        NS           0.011
  Visual Analog Scale rating ΔE~max~                                                                                                          
  Any drug effect                              71 ± 28 (111)         76 ± 21 (37)         96 (1)                0.44   NS        NS           0.005
  Good drug effect                             71 ± 30 (111)         76 ± 25 (37)         100 (1)               0.44   NS        NS           0.006
  Bad drug effect                              13 ± 24 (111)         25 ± 26 (37)         0 (1)                 3.09   0.049\*   NS           0.039
  Drug liking                                  73 ± 29 (111)         77 ± 28 (37)         100 (1)               0.40   NS        NS           0.005
  Stimulated                                   59 ± 35 (111)         71 ± 31 (37)         100 (1)               1.64   NS        NS           0.020
  High mood                                    68 ± 33 (111)         70 ± 32 (37)         100 (1)               0.28   NS        NS           0.004
  Concentration                                8.9 ± 16 (111)        6.3 ± 15 (37)        50 (1)                3.92   0.022\*   NS           0.051
  Talkative                                    22 ± 18 (111)         19 ± 21 (37)         50 (1)                1.58   NS        NS           0.020
  Appetite                                     -11 ± 29 (53)         2.4 ± 35 (18)        1.0 (1)               1.35   NS        NS           0.037
  Tired                                        21 ± 32 (80)          18 ± 34 (28)         30 (1)                0.14   NS        NS           0.002
  Fear                                         5.5 ± 16 (73)         9.5 ± 17 (23)        0 (1)                 0.61   NS        NS           0.013
  Happy                                        27 ± 19 (78)          26 ± 19 (27)         50 (1)                0.62   NS        NS           0.011
  Want to be hugged                            13 ± 18 (58)          14 ± 19 (19)         NA (0)                0.01   NS        NS           0.000
  Want to hug                                  13 ± 18 (58)          15 ± 18 (19)         NA (0)                0.03   NS        NS           0.000
  Vital signs parameters ΔE~max~                                                                                                              
  Systolic blood pressure, mmHg                23 ± 13 (111)         26 ± 11 (37)         43 (1)                1.52   NS        NS           0.019
  Diastolic blood pressure, mmHg               13 ± 9 (111)          15 ± 11 (37)         20 (1)                0.65   NS        NS           0.008
  Mean arterial pressure, mmHg                 16 ± 9 (111)          19 ± 10 (37)         29 (1)                1.33   NS        NS           0.017
  Heat rate beat/min                           16 ± 14 (111)         20 ± 14 (37)         54 (1)                3.89   0.023\*   NS           0.050
  Rate pressure product, mmHg/min              4,240 ± 2,838 (111)   4,972 ± 2,700 (37)   11,050 (1)            3.24   0.042\*   NS           0.041
  Body temperature, °C                         0.2 ± 0.5 (111)       0.3 ± 0.4 (37)       0.6 (1)               0.65   NS        NS           0.009
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                  
  Activity                                     2.4 ± 5.3 (111)       2.0 ± 3.9 (37)       16 (1)                3.74   0.026\*   NS           0.049
  High mood                                    3 ± 3.2 (111)         2.3 ± 2.8 (37)       8.0 (1)               1.92   NS        NS           0.026
  Fear/depression                              1.1 ± 3.2 (111)       1.2 ± 3.7 (37)       0 (1)                 0.07   NS        NS           0.001

N, number of subjects; SD, standard deviation; NS, not significant; Δ, values are change scores from placebo; ^a^p value additionally corrected for multiple comparisons according to the Nyholt method; η^2^, eta square; \*, uncorrected p \< 0.05.

###### 

Effects of polymorphisms in the dopamine transporter 1 gene on the maximal response to 125 mg MDMA (mean ± SD (N) and statistics) corrected with MDMA AUC~6~ (exclusive plasma concentrations).

  DAT1 3'-UTR rs28363170                       99                   910                  1010                 F       p value       p value^a^            η^2^
  -------------------------------------------- -------------------- -------------------- -------------------- ------- ------------- --------------------- ---------------
  N                                            8                    56                   79                                                               
  Female, N \[%\]                              2 \[25\]             29 \[52\]            41 \[52\]                                                        
  Drug experience, N \[%\]                     4 \[50\]             18 \[32\]            31 \[39\]                                                        
  MDMA plasma concentration Cmax, ng/ml        221 ± 44 (8)         227 ± 46 (56)        230 ± 50 (79)        0.14    NS            NS                    0.002
  MDMA plasma concentration AUC~6~, ng\*h/ml   939 ± 183 (8)        958 ± 180 (56)       961 ± 214 (79)       0.04    NS            NS                    0.001
  Visual Analog Scale rating ΔE~max~                                                                                                                      
  Any drug effect                              78 ± 20 (8)          73 ± 26 (56)         71 ± 28 (79)         0.48    NS            NS                    0.006
  Good drug effect                             84 ± 21 (8)          73 ± 28 (56)         71 ± 30 (79)         0.97    NS            NS                    0.013
  Bad drug effect                              11 ± 21 (8)          15 ± 29 (56)         16 ± 22 (79)         0.14    NS            NS                    0.002
  Drug liking                                  83 ± 22 (8)          77 ± 26 (56)         70 ± 31 (79)         1.26    NS            NS                    0.017
  Stimulated                                   63 ± 35 (8)          60 ± 35 (56)         63 ± 35 (79)         0.09    NS            NS                    0.001
  High mood                                    79 ± 32 (8)          68 ± 34 (56)         67 ± 33 (79)         0.57    NS            NS                    0.008
  Concentration                                14 ± 22 (8)          7.3 ± 16 (56)        9.3 ± 16 (79)        0.76    NS            NS                    0.011
  Talkative                                    23 ± 16 (8)          19 ± 18 (56)         22 ± 19 (79)         0.56    NS            NS                    0.008
  Appetite                                     -20 ± 25 (7)         -2.6 ± 37 (28)       -7 ± 26 (35)         1.14    NS            NS                    0.032
  Tired                                        6.9 ± 37 (7)         17 ± 31 (44)         25 ± 33 (53)         1.38    NS            NS                    0.026
  Fear                                         6.3 ± 21 (7)         4.1 ± 9.5 (33)       8 ± 19 (55)          0.59    NS            NS                    0.013
  Happy                                        15 ± 16 (3)          27 ± 20 (40)         27 ± 18 (59)         0.37    NS            NS                    0.007
  Want to be hugged                            0 (1)                16 ± 20 (28)         10 ± 16 (44)         1.16    NS            NS                    0.030
  Want to hug                                  0 (1)                16 ± 19 (28)         11 ± 16 (44)         1.01    NS            NS                    0.027
  Vital signs parameters ΔE~max~                                                                                                                          
  Systolic blood pressure, mmHg                27 ± 15 (8)          25 ± 11 (56)         22 ± 14 (79)         1.06    NS            NS                    0.014
  Diastolic blood pressure, mmHg               21 ± 18 (8)          14 ± 8 (56)          12 ± 9 (79)          3.84    0.024\*       NS                    0.049
  Mean arterial pressure, mmHg                 25 ± 14 (8)          18 ± 8 (56)          16 ± 10 (79)         3.79    0.025\*       NS                    0.048
  Heat rate beat/min                           16 ± 8 (8)           18 ± 15 (56)         16 ± 15 (79)         0.28    NS            NS                    0.004
  Rate pressure product, mmHg/min              4,623 ± 2,214 (8)    4,684 ± 2,835 (56)   4,194 ± 2,970 (79)   0.54    NS            NS                    0.007
  Body temperature, °C                         0 ± 0.3 (8)          0.3 ± 0.5 (56)       0.2 ± 0.5 (79)       1.34    NS            NS                    0.019
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                              
  Activity                                     4.0 ± 5.2 (8)        2.0 ± 4.9 (56)       2.3 ± 5.2 (79)       0.53    NS            NS                    0.008
  High mood                                    2.6 ± 1.5 (8)        3.0 ± 3.2 (56)       2.7 ± 3.3 (79)       0.16    NS            NS                    0.002
  Fear/depression                              0.5 ± 2 (8)          1.5 ± 3.6 (56)       1 ± 3 (79)           0.64    NS            NS                    0.009
  **DAT1 Intron 8 rs3836790**                  **55**               **56**               **66**               **F**   **p value**   **p value** **^a^**   **η** **^2^**
  DAT1 rs6347                                  CC                   CT                   TT                   F       p value       p value^a^            η^2^
  N                                            7                    54                   85                                                               
  Female, N \[%\]                              3 \[43\]             25 \[46\]            46 \[54\]                                                        
  Drug experience, N \[%\]                     4 \[57\]             21 \[39\]            29 \[34\]                                                        
  MDMA plasma concentration Cmax, ng/ml        218 ± 43 (7)         225 ± 54 (54)        231 ± 45 (85)        0.48    NS            NS                    0.007
  MDMA plasma concentration AUC~6~, ng\*h/ml   894 ± 201 (7)        945 ± 211 (54)       972 ± 196 (85)       0.65    NS            NS                    0.009
  Visual Analog Scale rating ΔE~max~                                                                                                                      
  Any drug effect                              66 ± 20 (7)          69 ± 29 (54)         75 ± 26 (85)         0.59    NS            NS                    0.007
  Good drug effect                             69 ± 26 (7)          72 ± 30 (54)         74 ± 28 (85)         0.05    NS            NS                    0.001
  Bad drug effect                              -0.7 ± 19 (7)        18 ± 29 (54)         16 ± 21 (85)         1.57    NS            NS                    0.020
  Drug liking                                  79 ± 20 (7)          73 ± 29 (54)         74 ± 30 (85)         0.24    NS            NS                    0.003
  Stimulated                                   58 ± 33 (7)          58 ± 35 (54)         66 ± 34 (85)         0.70    NS            NS                    0.009
  High mood                                    65 ± 27 (7)          66 ± 36 (54)         71 ± 31 (85)         0.19    NS            NS                    0.003
  Concentration                                -0.6 ± 5 (7)         9.2 ± 18 (54)        8.5 ± 15 (85)        1.18    NS            NS                    0.016
  Talkative                                    15 ± 15 (7)          20 ± 19 (54)         22 ± 19 (85)         0.37    NS            NS                    0.005
  Appetite                                     -21 ± 29 (3)         -9.8 ± 34 (25)       -4.9 ± 30 (43)       0.49    NS            NS                    0.014
  Tired                                        -10 ± 28 (5)         20 ± 33 (41)         22 ± 31 (61)         1.82    NS            NS                    0.032
  Fear                                         1.7 ± 2.9 (3)        4.7 ± 14 (35)        7.7 ± 18 (58)        0.48    NS            NS                    0.010
  Happy                                        20 ± 16 (4)          26 ± 19 (42)         29 ± 19 (57)         0.28    NS            NS                    0.005
  Want to be hugged                            9.8 ± 20 (4)         13 ± 19 (29)         14 ± 18 (42)         0.05    NS            NS                    0.001
  Want to hug                                  8.5 ± 17 (4)         14 ± 19 (29)         14 ± 18 (42)         0.06    NS            NS                    0.001
  Vital signs parameters ΔE~max~                                                                                                                          
  Systolic blood pressure, mmHg                31 ± 7 (7)           24 ± 12 (54)         23 ± 14 (85)         2.00    NS            NS                    0.026
  Diastolic blood pressure, mmHg               18 ± 6 (7)           15 ± 11 (54)         12 ± 8 (85)          2.99    0.05          NS                    0.038
  Mean arterial pressure, mmHg                 23 ± 6 (7)           18 ± 10 (54)         16 ± 10 (85)         3.67    0.028\*       NS                    0.046
  Heat rate beat/min                           16 ± 5 (7)           19 ± 15 (54)         17 ± 14 (85)         0.38    NS            NS                    0.005
  Rate pressure product, mmHg/min              4,394 ± 1,421 (7)    4,878 ± 2,775 (54)   4,264 ± 2,999 (85)   0.96    NS            NS                    0.013
  Body temperature, °C                         0.6 ± 0.6 (7)        0.3 ± 0.5 (54)       0.2 ± 0.5 (85)       2.59    0.08          NS                    0.035
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                              
  Activity                                     1.7 ± 3.1 (7)        2.2 ± 5.9 (54)       2.4 ± 4.7 (85)       0.08    NS            NS                    0.001
  High mood                                    2.3 ± 1.9 (7)        2.7 ± 3.3 (54)       3.0 ± 3.2 (85)       0.29    NS            NS                    0.004
  Hear/depression                              -1.1 ± 2.8 (7)       1.4 ± 3.2 (54)       1.2 ± 3.5 (85)       1.80    NS            NS                    0.025
  DAT1 rs11133767                              CC                   CT                   TT                   F       p value       p value^a^            η^2^
  N                                            12                   60                   77                                                               
  Female, N \[%\]                              6 \[50\]             29 \[48\]            41 \[53\]                                                        
  Drug experience, N \[%\]                     5 \[42\]             23 \[38\]            27 \[35\]                                                        
  MDMA plasma concentration Cmax, ng/ml        225 ± 46 (12)        224 ± 50 (60)        232 ± 48 (77)        0.45    NS            NS                    0.006
  MDMA plasma concentration AUC~6~, ng\*h/ml   933 ± 221 (12)       947 ± 192 (60)       973 ± 210 (77)       0.39    NS            NS                    0.005
  Visual Analog Scale rating ΔE~max~                                                                                                                      
  Any drug effect                              68 ± 24 (12)         70 ± 29 (60)         76 ± 25 (77)         0.73    NS            NS                    0.008
  Good drug effect                             70 ± 26 (12)         71 ± 30 (60)         74 ± 28 (77)         0.12    NS            NS                    0.002
  Bad drug effect                              3.9 ± 18 (12)        17 ± 29 (60)         17 ± 21 (77)         1.47    NS            NS                    0.019
  Drug liking                                  77 ± 23 (12)         72 ± 30 (60)         75 ± 29 (77)         0.16    NS            NS                    0.002
  Stimulated                                   65 ± 29 (12)         56 ± 36 (60)         67 ± 33 (77)         1.37    NS            NS                    0.017
  High mood                                    68 ± 28 (12)         66 ± 36 (60)         71 ± 31 (77)         0.16    NS            NS                    0.002
  Concentration                                3.7 ± 10 (12)        8.4 ± 18 (60)        9.4 ± 15 (77)        0.69    NS            NS                    0.009
  Talkative                                    22 ± 15 (12)         19 ± 20 (60)         22 ± 18 (77)         0.29    NS            NS                    0.004
  Appetite                                     -4.1 ± 25 (7)        -13 ± 33 (27)        -3.8 ± 30 (38)       0.71    NS            NS                    0.020
  Tired                                        12 ± 36 (10)         20 ± 31 (42)         22 ± 33 (57)         0.28    NS            NS                    0.005
  Fear                                         1.0 ± 1.9 (7)        4.6 ± 13 (40)        8.5 ± 19 (50)        1.09    NS            NS                    0.023
  Happy                                        25 ± 15 (7)          25 ± 20 (45)         29 ± 19 (54)         0.36    NS            NS                    0.007
  Want to be hugged                            11 ± 17 (5)          11 ± 18 (33)         15 ± 19 (39)         0.30    NS            NS                    0.008
  Want to hug                                  10 ± 15 (5)          10 ± 17 (33)         16 ± 18 (39)         0.70    NS            NS                    0.017
  Vital signs parameters ΔE~max~                                                                                                                          
  Systolic blood pressure, mmHg                29 ± 8 (12)          24 ± 13 (60)         23 ± 13 (77)         1.87    NS            NS                    0.024
  Diastolic blood pressure, mmHg               17 ± 7 (12)          14 ± 11 (60)         12 ± 8 (77)          2.19    NS            NS                    0.027
  Mean arterial pressure, mmHg                 22 ± 6 (12)          18 ± 10 (60)         16 ± 10 (77)         2.87    0.06          NS                    0.035
  Heat rate beat/min                           16 ± 12 (12)         17 ± 15 (60)         18 ± 14 (77)         0.03    NS            NS                    0.000
  Rate pressure product, mmHg/min              4,592 ± 2,500 (12)   4,550 ± 2,840 (60)   4,384 ± 2,950 (77)   0.14    NS            NS                    0.002
  Body temperature, °C                         0.4 ± 0.6 (12)       0.2 ± 0.5 (60)       0.2 ± 0.5 (77)       1.13    NS            NS                    0.015
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                              
  Activity                                     3.3 ± 5.1 (12)       2.3 ± 5.7 (60)       2.4 ± 4.6 (77)       0.23    NS            NS                    0.003
  High mood                                    3.7 ± 2.6 (12)       2.6 ± 3.2 (60)       2.9 ± 3.2 (77)       0.66    NS            NS                    0.009
  Fear/depression                              -0.8 ± 2 (12)        1.2 ± 3.3 (60)       1.4 ± 3.4 (77)       2.28    NS            NS                    0.030
  DAT1 rs11564774                              CC                   CG                   GG                   F       p value       p value^a^            η^2^
  N                                            62                   66                   20                                                               
  Female, N \[%\]                              33 \[53\]            35 \[53\]            7 \[35\]                                                         
  Drug experience, N \[%\]                     22 \[35\]            18 \[27\]            14 \[70\]                                                        
  MDMA plasma concentration Cmax, ng/ml        230 ± 48 (62)        230 ± 48 (66)        213 ± 50 (20)        1.05    NS            NS                    0.014
  MDMA plasma concentration AUC~6~, ng\*h/ml   965 ± 210 (62)       977 ± 200 (66)       876 ± 179 (20)       1.98    NS            NS                    0.027
  Visual Analog Scale rating ΔE~max~                                                                                                                      
  Any drug effect                              75 ± 25 (62)         69 ± 28 (66)         74 ± 23 (20)         1.70    NS            NS                    0.019
  Good drug effect                             74 ± 28 (62)         70 ± 30 (66)         77 ± 26 (20)         1.38    NS            NS                    0.018
  Bad drug effect                              18 ± 23 (62)         14 ± 25 (66)         16 ± 29 (20)         0.73    NS            NS                    0.009
  Drug liking                                  74 ± 31 (62)         72 ± 29 (66)         82 ± 23 (20)         1.72    NS            NS                    0.022
  Stimulated                                   68 ± 32 (62)         57 ± 36 (66)         63 ± 35 (20)         2.37    0.10          NS                    0.029
  High mood                                    71 ± 32 (62)         65 ± 34 (66)         72 ± 34 (20)         1.40    NS            NS                    0.018
  Concentration                                9.5 ± 16 (62)        7.8 ± 16 (66)        8.6 ± 16 (20)        0.19    NS            NS                    0.003
  Talkative                                    23 ± 19 (62)         19 ± 19 (66)         21 ± 17 (20)         0.61    NS            NS                    0.008
  Appetite                                     -2.9 ± 29 (32)       -8.6 ± 30 (27)       -15 ± 35 (13)        1.21    NS            NS                    0.034
  Tired                                        25 ± 34 (45)         19 ± 28 (47)         10 ± 37 (17)         1.13    NS            NS                    0.020
  Fear                                         8.9 ± 20 (44)        1.8 ± 4.9 (37)       11 ± 20 (15)         2.57    0.08          NS                    0.053
  Happy                                        27 ± 19 (42)         26 ± 19 (52)         30 ± 17 (11)         0.87    NS            NS                    0.016
  Want to be hugged                            10 ± 16 (30)         15 ± 19 (39)         14 ± 22 (7)          0.44    NS            NS                    0.011
  Want to hug                                  11 ± 16 (30)         15 ± 18 (39)         14 ± 22 (7)          0.38    NS            NS                    0.010
  Vital signs parameters ΔE~max~                                                                                                                          
  Systolic blood pressure, mmHg                22 ± 13 (62)         25 ± 13 (66)         23 ± 12 (20)         1.43    NS            NS                    0.018
  Diastolic blood pressure, mmHg               12 ± 8 (62)          14 ± 9 (66)          15 ± 12 (20)         1.83    NS            NS                    0.023
  Mean arterial pressure, mmHg                 16 ± 9 (62)          18 ± 9 (66)          19 ± 11 (20)         1.86    NS            NS                    0.023
  Heat rate beat/min                           17 ± 15 (62)         18 ± 15 (66)         18 ± 12 (20)         0.05    NS            NS                    0.001
  Rate pressure product, mmHg/min              4,337 ± 3,024 (62)   4,600 ± 2,817 (66)   4,551 ± 2,573 (20)   0.23    NS            NS                    0.003
  Body temperature, °C                         0.2 ± 0.5 (62)       0.3 ± 0.5 (66)       0.3 ± 0.5 (20)       0.72    NS            NS                    0.010
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                              
  Activity                                     3.2 ± 4.9 (62)       2 ± 5.7 (66)         1.4 ± 2.9 (20)       1.23    NS            NS                    0.017
  High mood                                    3.1 ± 3.3 (62)       2.7 ± 3.3 (66)       2.4 ± 2.1 (20)       0.42    NS            NS                    0.006
  Fear/depression                              1.0 ± 3.6 (62)       1.4 ± 3.3 (66)       0.6 ± 2 (20)         0.42    NS            NS                    0.006
  DAT1 rs460000                                GG                   GT                   TT                   F       p value       p value^a^            η^2^
  N                                            81                   58                   10                                                               
  Female, N \[%\]                              43 \[53\]            32 \[55\]            1 \[10\]                                                         
  Drug experience, N \[%\]                     31 \[38\]            17 \[29\]            7 \[70\]                                                         
  MDMA plasma concentration Cmax, ng/ml        230 ± 49 (81)        230 ± 49 (58)        199 ± 35 (10)        1.96    NS            NS                    0.026
  MDMA plasma concentration AUC~6~, ng\*h/ml   967 ± 211 (81)       967 ± 196 (58)       851 ± 155 (10)       1.55    NS            NS                    0.021
  Visual Analog Scale rating ΔE~max~                                                                                                                      
  Any drug effect                              72 ± 27 (81)         73 ± 27 (58)         74 ± 23 (10)         0.60    NS            NS                    0.007
  Good drug effect                             71 ± 29 (81)         75 ± 28 (58)         75 ± 27 (10)         0.59    NS            NS                    0.007
  Bad drug effect                              17 ± 22 (81)         16 ± 26 (58)         13 ± 36 (10)         0.03    NS            NS                    0.000
  Drug liking                                  71 ± 31 (81)         77 ± 27 (58)         78 ± 21 (10)         0.95    NS            NS                    0.012
  Stimulated                                   64 ± 34 (81)         62 ± 36 (58)         51 ± 30 (10)         0.29    NS            NS                    0.004
  High mood                                    69 ± 32 (81)         68 ± 35 (58)         73 ± 29 (10)         0.40    NS            NS                    0.005
  Concentration                                9.0 ± 15 (81)        7.4 ± 16 (58)        11 ± 20 (10)         0.29    NS            NS                    0.004
  Talkative                                    23 ± 19 (81)         19 ± 19 (58)         20 ± 11 (10)         0.55    NS            NS                    0.007
  Appetite                                     -4.8 ± 28 (36)       -6.4 ± 34 (29)       -24 ± 27 (7)         1.51    NS            NS                    0.041
  Tired                                        24 ± 33 (54)         16 ± 31 (46)         12 ± 29 (9)          1.00    NS            NS                    0.018
  Fear                                         8 ± 19 (55)          2.5 ± 5.8 (35)       13 ± 25 (7)          1.86    NS            NS                    0.038
  Happy                                        27 ± 18 (60)         28 ± 20 (41)         21 ± 14 (5)          0.05    NS            NS                    0.001
  Want to be hugged                            10 ± 16 (45)         19 ± 21 (29)         0 ± 0 (3)            2.36    NS            NS                    0.056
  Want to hug                                  11 ± 16 (45)         19 ± 20 (29)         0 ± 0 (3)            2.26    NS            NS                    0.053
  Vital signs parameters ΔE~max~                                                                                                                          
  Systolic blood pressure, mmHg                23 ± 14 (81)         25 ± 11 (58)         24 ± 12 (10)         0.49    NS            NS                    0.006
  Diastolic blood pressure, mmHg               13 ± 9 (81)          14 ± 8 (58)          18 ± 17 (10)         2.97    0.05          NS                    0.037
  Mean arterial pressure, mmHg                 16 ± 10 (81)         18 ± 8 (58)          22 ± 13 (10)         2.90    0.06          NS                    0.036
  Heat rate beat/min                           16 ± 15 (81)         19 ± 15 (58)         16 ± 7 (10)          0.66    NS            NS                    0.009
  Rate pressure product, mmHg/min              4,219 ± 2,944 (81)   4,902 ± 2,877 (58)   3,963 ± 1,624 (10)   1.03    NS            NS                    0.013
  Body temperature, °C                         0.2 ± 0.5 (81)       0.3 ± 0.4 (58)       0.3 ± 0.6 (10)       0.73    NS            NS                    0.010
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                              
  Activity                                     2.5 ± 5.2 (81)       2.4 ± 5.3 (58)       2.0 ± 2.7 (10)       0.02    NS            NS                    0.000
  High mood                                    2.8 ± 3.3 (81)       3.0 ± 3.2 (58)       2.2 ± 1.3 (10)       0.26    NS            NS                    0.004
  Fear/depression                              0.9 ± 3 (81)         1.4 ± 3.7 (58)       1.2 ± 1.5 (10)       0.46    NS            NS                    0.006
  DAT1 rs463379                                CC                   CG                   GG                   F       p value       p value^a^            η^2^
  N                                            94                   48                   7                                                                
  Female, N \[%\]                              52 \[55\]            22 \[46\]            2 \[29\]                                                         
  Drug experience, N \[%\]                     33 \[35\]            20 \[42\]            2 \[29\]                                                         
  MDMA plasma concentration Cmax, ng/ml        232 ± 50 (94)        221 ± 47 (48)        221 ± 37 (7)         0.98    NS            NS                    0.013
  MDMA plasma concentration AUC~6~, ng\*h/ml   971 ± 200 (94)       937 ± 214 (48)       958 ± 185 (7)        0.46    NS            NS                    0.006
  Visual Analog Scale rating ΔE~max~                                                                                                                      
  Any drug effect                              73 ± 26 (94)         71 ± 28 (48)         72 ± 20 (7)          0.01    NS            NS                    0.000
  Good drug effect                             75 ± 28 (94)         69 ± 31 (48)         67 ± 26 (7)          0.68    NS            NS                    0.009
  Bad drug effect                              18 ± 26 (94)         14 ± 21 (48)         9.1 ± 17 (7)         0.57    NS            NS                    0.007
  Drug liking                                  77 ± 27 (94)         69 ± 33 (48)         65 ± 27 (7)          1.27    NS            NS                    0.016
  Stimulated                                   61 ± 35 (94)         66 ± 33 (48)         57 ± 37 (7)          0.71    NS            NS                    0.009
  High mood                                    70 ± 33 (94)         67 ± 32 (48)         64 ± 33 (7)          0.14    NS            NS                    0.002
  Concentration                                9.1 ± 17 (94)        7.9 ± 15 (48)        5.4 ± 11 (7)         0.23    NS            NS                    0.003
  Talkative                                    23 ± 19 (94)         18 ± 18 (48)         17 ± 20 (7)          0.86    NS            NS                    0.011
  Appetite                                     -6.8 ± 33 (53)       -6.7 ± 26 (15)       -15 ± 16 (4)         0.11    NS            NS                    0.003
  Tired                                        19 ± 32 (72)         22 ± 34 (32)         19 ± 23 (5)          0.23    NS            NS                    0.004
  Fear                                         6.4 ± 18 (66)        5 ± 9.5 (27)         14 ± 10 (4)          0.56    NS            NS                    0.012
  Happy                                        28 ± 19 (65)         25 ± 19 (38)         24 ± 25 (3)          0.32    NS            NS                    0.006
  Want to be hugged                            16 ± 20 (41)         8.6 ± 15 (33)        20 ± 26 (3)          1.85    NS            NS                    0.044
  Want to hug                                  16 ± 19 (41)         8.8 ± 14 (33)        22 ± 26 (3)          2.12    NS            NS                    0.050
  Vital signs parameters ΔE~max~                                                                                                                          
  Systolic blood pressure, mmHg                23 ± 13 (94)         24 ± 13 (48)         26 ± 15 (7)          0.35    NS            NS                    0.005
  Diastolic blood pressure, mmHg               14 ± 10 (94)         13 ± 9 (48)          12 ± 6 (7)           0.16    NS            NS                    0.002
  Mean arterial pressure, mmHg                 17 ± 10 (94)         17 ± 9 (48)          16 ± 7 (7)           0.11    NS            NS                    0.001
  Heat rate beat/min                           17 ± 14 (94)         17 ± 13 (48)         22 ± 21 (7)          0.32    NS            NS                    0.004
  Rate pressure product, mmHg/min              4,500 ± 2,891 (94)   4,239 ± 2,512 (48)   5,607 ± 4,506 (7)    0.66    NS            NS                    0.009
  Body temperature, °C                         0.2 ± 0.5 (94)       0.3 ± 0.5 (48)       0.2 ± 0.6 (7)        0.84    NS            NS                    0.011
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                              
  Activity                                     2.4 ± 5.7 (94)       2.1 ± 4.0 (48)       4.0 ± 2.4 (7)        0.42    NS            NS                    0.006
  High mood                                    3 ± 3.1 (94)         2.5 ± 3.3 (48)       3.7 ± 3.5 (7)        0.63    NS            NS                    0.009
  Fear/depression                              1.2 ± 3.2 (94)       1.4 ± 3.6 (48)       -1.4 ± 3.6 (7)       2.25    NS            NS                    0.030
  N                                            7                    47                   93                                                               
  Female, N \[%\]                              2 \[29\]             21 \[45\]            51 \[55\]                                                        
  Drug experience, N \[%\]                     2 \[29\]             20 \[43\]            32 \[34\]                                                        
  MDMA plasma concentration Cmax, ng/ml        221 ± 37 (7)         221 ± 47 (47)        232 ± 50 (93)        0.86    NS            NS                    0.012
  MDMA plasma concentration AUC~6~, ng\*h/ml   958 ± 185 (7)        934 ± 215 (47)       970 ± 200 (93)       0.49    NS            NS                    0.007
  Visual Analog Scale rating ΔE~max~                                                                                                                      
  Any drug effect                              72 ± 20 (7)          71 ± 28 (47)         73 ± 26 (93)         0.00    NS            NS                    0.000
  Good drug effect                             67 ± 26 (7)          69 ± 31 (47)         75 ± 28 (93)         0.60    NS            NS                    0.008
  Bad drug effect                              9.1 ± 17 (7)         13 ± 21 (47)         18 ± 27 (93)         0.62    NS            NS                    0.008
  Drug liking                                  65 ± 27 (7)          69 ± 33 (47)         77 ± 27 (93)         1.19    NS            NS                    0.016
  Stimulated                                   57 ± 37 (7)          65 ± 33 (47)         61 ± 35 (93)         0.68    NS            NS                    0.009
  High mood                                    64 ± 33 (7)          67 ± 32 (47)         70 ± 33 (93)         0.10    NS            NS                    0.001
  Concentration                                5.4 ± 11 (7)         8.1 ± 15 (47)        9.2 ± 17 (93)        0.23    NS            NS                    0.003
  Talkative                                    17 ± 20 (7)          19 ± 18 (47)         23 ± 19 (93)         0.64    NS            NS                    0.009
  Appetite                                     -15 ± 16 (4)         -6.7 ± 26 (15)       -6.8 ± 33 (53)       0.11    NS            NS                    0.003
  Tired                                        19 ± 23 (5)          22 ± 34 (32)         19 ± 32 (72)         0.23    NS            NS                    0.004
  Fear                                         14 ± 10 (4)          5 ± 9.5 (27)         6.4 ± 18 (66)        0.56    NS            NS                    0.012
  Happy                                        24 ± 25 (3)          25 ± 19 (37)         28 ± 18 (64)         0.23    NS            NS                    0.004
  Want to be hugged                            20 ± 26 (3)          7.7 ± 14 (32)        15 ± 19 (40)         2.02    NS            NS                    0.050
  Want to hug                                  22 ± 26 (3)          8.1 ± 14 (32)        15 ± 19 (40)         2.22    NS            NS                    0.054
  Vital signs parameters ΔE~max~                                                                                                                          
  Systolic blood pressure, mmHg                26 ± 15 (7)          24 ± 14 (47)         23 ± 13 (93)         0.27    NS            NS                    0.004
  Diastolic blood pressure, mmHg               12 ± 6 (7)           13 ± 9 (47)          14 ± 10 (93)         0.15    NS            NS                    0.002
  Mean arterial pressure, mmHg                 16 ± 7 (7)           17 ± 9 (47)          17 ± 10 (93)         0.09    NS            NS                    0.001
  Heat rate beat/min                           22 ± 21 (7)          17 ± 13 (47)         17 ± 14 (93)         0.30    NS            NS                    0.004
  Rate pressure product, mmHg/min              5,607 ± 4,506 (7)    4,245 ± 2,539 (47)   4,514 ± 2,903 (93)   0.64    NS            NS                    0.009
  Body temperature, °C                         0.2 ± 0.6 (7)        0.3 ± 0.5 (47)       0.2 ± 0.5 (93)       0.67    NS            NS                    0.009
  Adjective Mood Rating Scale rating ΔE~max~                                                                                                              
  Activity                                     4.0 ± 2.4 (7)        2.1 ± 4.1 (47)       2.4 ± 5.7 (93)       0.41    NS            NS                    0.006
  High mood                                    3.7 ± 3.5 (7)        2.5 ± 3.3 (47)       2.9 ± 3.1 (93)       0.57    NS            NS                    0.008
  Fear/depression                              -1.4 ± 3.6 (7)       1.4 ± 3.6 (47)       1.2 ± 3.2 (93)       2.27    NS            NS                    0.031

N, number of subjects; SD, standard deviation; NS, not significant; Δ, values are change scores from placebo; ^a^p value additionally corrected for multiple comparisons according to the Nyholt method; η^2^, eta square; \*, uncorrected p \< 0.05.

###### 

Effects of the variable-number tandem repeat polymorphism in the dopamine receptor D4 gene on the maximal response to 125 mg MDMA (mean ± SD (N) and statistics) corrected with MDMA AUC~6~ (exclusive plasma concentrations).

  DRD4 VNTR                                    ≤8 Repeats           \>8 Repeats          F      p value   p value^a^   η^2^
  -------------------------------------------- -------------------- -------------------- ------ --------- ------------ -------
  N                                            87                   59                                                 
  Female, N \[%\]                              44 \[51\]            31 \[53\]                                          
  Drug experience, N \[%\]                     31 \[36\]            22 \[37\]                                          
  MDMA plasma concentration Cmax, ng/ml        229 ± 44 (87)        226 ± 55 (59)        0.16   NS        NS           0.001
  MDMA plasma concentration AUC~6~, ng\*h/ml   965 ± 189 (87)       948 ± 221 (59)       0.25   NS        NS           0.002
  Visual Analog Scale rating ΔE~max~                                                                                   
  Any drug effect                              74 ± 26 (87)         71 ± 26 (59)         0.35   NS        NS           0.002
  Good drug effect                             73 ± 30 (87)         73 ± 26 (59)         0.01   NS        NS           0.000
  Bad drug effect                              17 ± 23 (87)         15 ± 27 (59)         0.08   NS        NS           0.001
  Drug liking                                  74 ± 31 (87)         75 ± 25 (59)         0.12   NS        NS           0.001
  Stimulated                                   63 ± 35 (87)         63 ± 34 (59)         0.07   NS        NS           0.000
  High mood                                    68 ± 34 (87)         71 ± 31 (59)         0.51   NS        NS           0.003
  Concentration                                8.2 ± 17 (87)        9.0 ± 15 (59)        0.09   NS        NS           0.001
  Talkative                                    20 ± 19 (87)         23 ± 19 (59)         1.27   NS        NS           0.008
  Appetite                                     -5.8 ± 33 (47)       -10 ± 26 (25)        0.41   NS        NS           0.006
  Tired                                        24 ± 32 (68)         13 ± 32 (41)         2.63   NS        NS           0.023
  Fear                                         6.6 ± 18 (56)        5.6 ± 14 (38)        0.08   NS        NS           0.001
  Happy                                        26 ± 20 (59)         30 ± 17 (44)         1.33   NS        NS           0.012
  Want to be hugged                            13 ± 19 (40)         13 ± 18 (34)         0.01   NS        NS           0.000
  Want to hug                                  14 ± 19 (40)         13 ± 17 (34)         0.02   NS        NS           0.000
  Vital signs parameters ΔE~max~                                                                                       
  Systolic blood pressure, mmHg                25 ± 12 (87)         22 ± 13 (59)         1.24   NS        NS           0.008
  Diastolic blood pressure, mmHg               14 ± 9 (87)          13 ± 10 (59)         0.11   NS        NS           0.001
  Mean arterial pressure, mmHg                 17 ± 9 (87)          17 ± 10 (59)         0.11   NS        NS           0.001
  Heat rate beat/min                           18 ± 15 (87)         17 ± 14 (59)         0.03   NS        NS           0.000
  Rate pressure product, mmHg/min              4,561 ± 2,967 (87)   4,393 ± 2,746 (59)   0.06   NS        NS           0.000
  Body temperature, °C                         0.3 ± 0.5 (87)       0.2 ± 0.5 (59)       0.19   NS        NS           0.001
  Adjective Mood Rating Scale rating ΔE~max~                                                                           
  Activity                                     2.3 ± 5.2 (87)       2.7 ± 4.9 (59)       0.26   NS        NS           0.002
  High mood                                    2.8 ± 3.3 (87)       3.0 ± 3.0 (59)       0.18   NS        NS           0.001
  Fear/depression                              1.1 ± 3.7 (87)       0.9 ± 3 (59)         0.10   NS        NS           0.001

N, number of subjects; SD, standard deviation; NS, not significant; Δ, values are change scores from placebo; ^a^p value additionally corrected for multiple comparisons according to the Nyholt method; η^2^, eta square.

The 60-item Likert-type scale of the short version of the Adjective Mood Rating Scale (AMRS) ([@B59]) was administered before and 1.25, 2, and 5 h after MDMA or placebo administration. The AMRS contains subscales for activity, well-being, and anxiety--depression.

Genotyping {#s2_6}
----------

Genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hombrechtikon, Switzerland) and automated QIAcube system. SNP genotyping was performed using commercial TaqMan SNP genotyping assays (LuBio Science, Lucerne, Switzerland). We assayed the following SNPs: DRD2/ankyrin repeat and kinase domain containing 1 (ANKK1) SNPs rs1800497 (assay: C\_\_\_7486676_10), DRD2 rs6277 (assay: C\_\_11339240_10), and rs1079597 (assay: C\_\_\_2278884_10), and DAT1 SNPs rs6347 (assay: C\_\_\_8769902_10) and rs11133767 (assay: C\_\_\_3024834_10) and rs11564774 (assay: C\_\_25761679_10) and rs460000 (assay: C\_\_\_3284837_10) and rs463379 (assay: C\_\_\_3284827_10). We also used the following method to genotype the polymorphisms in DRD4 exon III VNTR, DAT1 3'UTR VNTR rs28363170, and DAT1 Intron 8 (5/6) VNTR rs3836790. Genotypes were determined by polymerase chain reaction (PCR) using 2.5, 1.25, and 1.25 units of HotStarTaq DNA polymerase (QIAGEN Instruments AG, Hombrechtikon, Switzerland), respectively; 1.5 µl PCR Buffer 10x each (15 mM Mg^2+^; QIAGEN Instruments AG, Hombrechtikon, Switzerland); 0.25, 1, and 1 µl dNTP Mix (40 mM), respectively; and primer set *5'-GCGACTACGTGGTCTACTCG* and *5'-AGGACCCTCATGGCCTTG, 5'-TGTGGTGTAGGGAACGGCCTGAG* and *5'-CTTCCTGGAGGTCACGGCTCAAGG*, and *5'-GCATGTGGATGTGTTCTTGCA* and *5'-TCATCCCAGGGACATCTGCTA* (both 1 µl, both 0.5 µl, and both 0.5 µl, respectively) in a total reaction volume of 15 µl each. The following temperature profile was applied in a T100 thermal cycler (Bio-Rad, Cressier, Switzerland): for DRD4 (Exon III VNTR): initial activation step of 95°C (15 min) and 30 cycles of 98°C (60 s), 67.5°C (60 s), and 72°C (60 s), with final extension at 72°C (5 min); for DAT1 (3'UTR VNTR) rs28363170 and (intron8 5/6 VNTR) rs3836790: initial activation step of 95°C (15 min) and 30 cycles of 98°C (25 s), 95°C (35 s), and 72°C (45 s), with final extension at 72°C (5 min). The sizes of the resulting PCR products were assessed by 3.5% (for DRD4 exon III VNTR) and 2.5% (for DAT1 3'UTR VNTR rs28363170 and Intron 8 VNTR rs3836790) agarose gel electrophoresis. Amplicons of the DRD4 (Exon III VNTR in chromosome 11) of 379 bp were designated as 2 repeats (2R), and amplicons of every additional 48 bp were designated as 2+x times 48 bp variants \[up to 9R (with 379 bp + 7 × 48 bp = 715 bp)\]. Four and 7-repeat amplicons were the most common forms. Complete genotype and allele distributions are depicted in [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}. For the analysis, groups were made with cumulative ≤8 repeats or cumulative \>8 repeats in both alleles. Amplicons of the DAT1 (3'UTR VNTR) rs28363170 of 448 bp were designated as 9 repeats (9R), and amplicons of 488 bp were designated as 10R. Individuals possessing other repeats were excluded from the analysis. Amplicons of the DAT1 (intron 8 5/6 VNTR) rs3836790 of 295 bp were designated as 5 repeats (5R), and amplicons of 325 bp were designated as 6 repeats (6R). The pairwise linkage disequilibrium (LD) and relative physical location of the determined SNPs on chromosome 11 (DRD2) and 5 (DAT1) are shown in [**Supplementary Figure 1**](#SM5){ref-type="supplementary-material"}. The tested genetic variants were consistent with Hardy--Weinberg equilibrium (*p* \> 0.05).

Statistical Analysis {#s2_7}
--------------------

The statistical analyses were performed using Statistica 12 software (StatSoft, Tulsa, OK, USA). For repeatedly measured data, peak effects (E~max~) and areas under the effect-time curve (AUEC) from 0- to 6-h values were determined for MDMA and placebo. Differences in E~max~ (Δ; MDMA-placebo) were then analyzed using one-way analysis of variance (ANOVA), with genotype as the between-group factor. The level of significance was set at *p* \< 0.05. The Nyholt correction method was used to account for multiple comparisons and displayed separately in all tables ([@B60]). We thereby corrected for 17 subjective effect ratings (VAS+AMRS), and six vital parameters. In addition, this was then corrected for each of the 11 polymorphisms tested, resulting in (17 + 6) × 11 = 253 variables and an effective number of independent variables (V~eff~) of 183.6 according to Nyholt. Consequently, this led to a corrected significance threshold of p \< 0.00027 to keep Type I error rate at 5%. To account for differences in plasma concentrations of MDMA that were caused by differences in body weight, dosing, or metabolizing enzymes ([@B17], [@B18]), the area under the MDMA plasma concentration--time curve from 0 to 6 h (AUC) was included as a covariate in the ANOVAs, and we report the corrected statistics. Additionally, modulatory effects of sex were explored by adding sex as a between-subjects factor in the ANOVAs (sex × genotype). E~max~ values were obtained directly from the observed data. AUC and AUEC values were calculated using the linear-log trapezoidal method in Phoenix WinNonlin 6.4 (Certara, Princeton, NJ, USA). The primary analysis was performed using an additive genotype model approach for SNPs. Recessive or dominant model analysis was also performed, the results of which are reported only when the additive model was initially significant.

Results {#s3}
=======

MDMA significantly altered all tested VAS and AMRS E~max~ values. Subjects did not significantly differ in MDMA plasma concentration or previous drug experience across genotype groups, with the exception of DAT1 rs11133767. Participants carrying two T-alleles showed disproportionately more illicit drug experiences than carriers of the C-allele (70% vs. 31%, respectively; χ^2^ = 11.2, p \< 0.001).

The influence of polymorphisms within genes coding for the DRD2, DAT1, and DRD4 on the maximal acute subjective and autonomic effects of MDMA is shown in [**Tables 1**](#T1){ref-type="table"}--[**3**](#T3){ref-type="table"}, respectively. [**Supplementary Table S2**](#SM2){ref-type="supplementary-material"} shows the data for the total response to MDMA over time (AUEC). [**Supplementary Tables S3**](#SM3){ref-type="supplementary-material"} and [**S4**](#SM4){ref-type="supplementary-material"} show the uncorrected statistics for E~max~ and AUEC, respectively. Homozygous A-allele carriers of the DRD2 rs1800497 showed a higher score in VASs "talkative" (F~1,147~ = 4.23, p \< 0.05) and in AMRSs "activity" and "high mood" (F~1,147~ = 4.62, p \< 0.05 and F~1,147~ = 4.50, p \< 0.05, respectively) compared to carriers of the G-allele. Subjects with two 9R-alleles of the DAT1 rs28363170 had a higher MDMA-induced increase in diastolic blood pressure and MAP compared to subjects with a 10R-allele (F~1,141~ = 7.12, p \< 0.01 and F~1,141~ = 6.56, p \< 0.05, respectively). Regarding the DAT1 rs3836790, MDMA produced a higher increase in MAP in individuals homozygous for the 5R-allele compared to 6R-allele carriers (F~1,144~ = 4.31, p \< 0.05).

Nyholt correction for multiple comparisons yielded statistics indicating that the genetic polymorphisms had no significant effect on the subjective and autonomic parameters. Sex did not significantly modulate the results.

Discussion {#s4}
==========

The current study expands previous research on whether the acute effects of MDMA are modulated by common genetic polymorphisms in pharmacological targets of MDMA. So far, the focus lied on the role of the NE and 5-HT system genetics in the acute effects of MDMA ([@B22], [@B23]). This is the first study to concentrate on a selection of genetic polymorphisms within the human DA system (namely, D~2~, D~4~, and DAT).

Action on the DA system is thought to be crucial for the effects of most psychostimulant substances ([@B6], [@B24], [@B61]), and pharmacogenetic studies demonstrated that different phenotypes are affected by various DA genotypes. As for MDMA, however, none of the herein investigated genetic polymorphisms significantly altered the acute effects after consideration of Type I error correction.

Nevertheless, this missing link between DA genetic variations and MDMA-related phenotypes might not solely be caused by a lack of genetic influence on the MDMA effects but rather the potentially minor role of DA in MDMA effects. Although MDMA is an amphetamine, it acts mainly on the 5-HT system and therefore leads to its classification as an entactogen ([@B7], [@B62]).

The present study has limitations. Although this analysis was done using the largest sample of healthy human subjects who received MDMA in placebo-controlled studies, the sample size is still relatively small when considering the partially small rare allele groups and mostly weak effect sizes for the influence of genetic variants on the MDMA response. This is especially influencing spurious, uncorrected effects (i.e., the AA carrier group for the SNP DRD2/ANKK1 rs1800497 with N = 2). Larger cohorts might show a more balanced sample distribution, which might lead to different results. Additionally, the study was conducted in healthy volunteers with a single dose of 125 mg MDMA. Therefore, the findings may not be applied to other populations and situations, such as psychiatric patients and the use of higher doses of MDMA. Furthermore, SNPs in genes of other targets of MDMA may also be involved. However, we corrected for the modulatory effects of known genetic variants that influence the metabolism of MDMA ([@B17], [@B18]) by taking interindividual differences in plasma MDMA concentrations into account. We also might have missed some relevant genetic polymorphisms. A novel potentially functional SNP within the DAT1 has been described in recent research. However, the SNP showed no significant alteration in the inhibition of DA uptake by MDMA in human embryonic kidney 293 cells ([@B63]). We have also not tested for rare haplotypes because a haplotype approach may lead to very small groups and more potential statistical artifacts. However, a haplotype suggested by Brewer et al., which consists of rs28363170 10/10 genotype and at least one rs3836790 5R-allele carriers, showed a reduced subjective response to cocaine compared to others ([@B40]). The same haplotype showed no effect in the present study. In fact, uncorrected results even implied opposite and incoherent effects, with 10R carriers showing lower MDMA-induced MAP changes and 5/5 carriers showing higher MAP changes than subjects with the 9/9 genotype or a 6R-allele, respectively. This incoherency may be attributable to the different substances used (cocaine vs. MDMA) and different cohorts (80% males of African descent vs. the sex-balanced sample of European descent) ([@B40]). Additionally, MDMA may interact with a different binding site on the DAT compared to other stimulants like cocaine ([@B64]). Finally, previous drug experiences were not equally distributed among DAT1 rs11133767 genotype groups, and effects might slightly depend on previous substance use experiences. Because of the involvement of DA in addiction, subjects carrying a TT genotype may be more prone to illicit substance use ([@B65]). Apart from this finding, given that our cohort included mostly drug-naive subjects with limited drug use experience, some alleles associated with increased drug use might even be underrepresented. However, the tested variants were consistent with the Hardy--Weinberg equilibrium and comparable with frequencies found in European genome databases.

We conclude that the present findings align with previous studies in that variations in genes coding for players of the monoaminergic systems are unlikely to explain interindividual variations in the acute effects of MDMA in humans.
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